Novacea cheered on decision to expand cancer trial
Novacea has disclosed that it has asked the FDA to boost enrollment in a late-stage trial of its prostate cancer drug, Asentar. The company, which reported widening second-quarter losses as a result of higher R&D spending, wants to enlist 1200 patients in Phase III rather than the 900 it originally set out to test. Bigger trials produce more reliable results. Novacea shares slid this morning on its numbers, even though the analysts were cheering the company's decision to expand its cancer trial.
- see Novacea's financial results
- read the AP report for more
Related Articles:
Novacea stock rockets up on $440M deal. Report
Novacea files $75M IPO. Report
Novacea raises $25M in third venture round. Report
Be the first to comment
More stories about Phase III FDA Venture Capital analysts Drug Trials cancer drug Prostate Cancer Biotech IPO Novacea
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
